NCT03106779 · OUTCOME

Overall Survival (OS) Per Event Free Percentage Per Kaplan-Meier Estimates

Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs · Source last updated 2026-08-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: Percentage of participants
Interval / dispersion: 95% Confidence Interval
Time frame: From the first dose of treatment to study completion, up to 5 years

What was measured

Overall survival is defined as the time from the date of randomization to the date of death (including the survival follow-up period) per Kaplan-Meier (KM).

Analysis population: The FAS comprised of all randomized participants. According to the intent to treat principle, participants were analyzed according to the treatment and stratum were assigned at randomization.

Groups in this outcome

Asciminib

Participants randomized to asciminib 40mg BID

Bosutinib

Participants randomized to bosutinib 500mg QD

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Asciminib	157
Bosutinib	76

Reported measurements

1 year

Values in Percentage of participants · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Asciminib	97.3	Not reported	92.9	99.0	Not reported
Bosutinib	98.6	Not reported	90.2	99.8	Not reported

3 years

Values in Percentage of participants · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Asciminib	92.4	Not reported	86.7	95.7	Not reported
Bosutinib	96.9	Not reported	88.0	99.2	Not reported

5 years

Values in Percentage of participants · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Asciminib	89.4	Not reported	83.1	93.5	Not reported
Bosutinib	90.0	Not reported	78.9	95.4	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
92.9
upper Limit
99.0
value
97.3
group Id
OG001
lower Limit
90.2
upper Limit
99.8
value
98.6
title
1 year
categories
measurements
group Id
OG000
lower Limit
86.7
upper Limit
95.7
value
92.4
group Id
OG001
lower Limit
88.0
upper Limit
99.2
value
96.9
title
3 years
categories
measurements
group Id
OG000
lower Limit
83.1
upper Limit
93.5
value
89.4
group Id
OG001
lower Limit
78.9
upper Limit
95.4
value
90.0
title
5 years

denoms

counts
group Id
OG000
value
157
group Id
OG001
value
76
units
Participants

description

Overall survival is defined as the time from the date of randomization to the date of death (including the survival follow-up period) per Kaplan-Meier (KM).

dispersion Type

95% Confidence Interval

groups

description
Participants randomized to asciminib 40mg BID
id
OG000
title
Asciminib
description
Participants randomized to bosutinib 500mg QD
id
OG001
title
Bosutinib

param Type

NUMBER

population Description

The FAS comprised of all randomized participants. According to the intent to treat principle, participants were analyzed according to the treatment and stratum were assigned at randomization.

reporting Status

POSTED

time Frame

From the first dose of treatment to study completion, up to 5 years

title

Overall Survival (OS) Per Event Free Percentage Per Kaplan-Meier Estimates

type

SECONDARY

unit Of Measure

Percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice